Search

Your search keyword '"Bozzani, S"' showing total 4 results
Start Over Author "Bozzani, S" Search Limiters Full Text
4 results on '"Bozzani, S"'

1. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis

Author

VIGANO', ILARIA, ANTOLINI, LAURA, PIAZZA, ROCCO GIOVANNI, GAMBACORTI PASSERINI, CARLO, Di Giacomo, N, Bozzani, S, Vigano', I, Di Giacomo, N, Bozzani, S, Antolini, L, Piazza, R, and GAMBACORTI PASSERINI, C

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Protein Kinase Inhibitor, Hematology, Middle Aged, Disease-Free Survival, Piperazines, Follow-Up Studie, Survival Rate, Pyrimidines, Benzamide, Pyrimidine, Retrospective Studie, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Imatinib Mesylate, Humans, Piperazine, Protein Kinase Inhibitors, Human, Aged, Follow-Up Studies, Retrospective Studies
Abstract

Imatinib mesylate radically changed the natural history of chronic myeloid leukemia (CML). The recent availability of alternative tyrosine kinase inhibitors (TKIs) renders the clinical management of CML more complex. In this article, we summarize our long-term single institution experience. From 2003 to 2012, 102 patients with newly diagnosed chronic phase CML were referred to our institution and treated with imatinib mesylate as first-line therapy. All patients were followed inside a dedicated CML clinic. At 1 year, 82/95 patients (86.3%) achieved complete cytogenetic response (CCyR) using a treatment performed analysis (TPA); when using an intention to treat analysis, 85/102 patients (83.3%) obtained CCyR. At 3 months, 58 patients (64.4% TPA) obtained a BCR-ABL transcripts level

Published
2014

2. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis

Author

Vigano', I, Di Giacomo, N, Bozzani, S, Antolini, L, Piazza, R, GAMBACORTI PASSERINI, C, VIGANO', ILARIA, ANTOLINI, LAURA, PIAZZA, ROCCO GIOVANNI, GAMBACORTI PASSERINI, CARLO, Vigano', I, Di Giacomo, N, Bozzani, S, Antolini, L, Piazza, R, GAMBACORTI PASSERINI, C, VIGANO', ILARIA, ANTOLINI, LAURA, PIAZZA, ROCCO GIOVANNI, and GAMBACORTI PASSERINI, CARLO

Abstract

Imatinib mesylate radically changed the natural history of chronic myeloid leukemia (CML). The recent availability of alternative tyrosine kinase inhibitors (TKIs) renders the clinical management of CML more complex. In this article, we summarize our long-term single institution experience. From 2003 to 2012, 102 patients with newly diagnosed chronic phase CML were referred to our institution and treated with imatinib mesylate as first-line therapy. All patients were followed inside a dedicated CML clinic. At 1 year, 82/95 patients (86.3%) achieved complete cytogenetic response (CCyR) using a treatment performed analysis (TPA); when using an intention to treat analysis, 85/102 patients (83.3%) obtained CCyR. At 3 months, 58 patients (64.4% TPA) obtained a BCR-ABL transcripts level <10%. A major molecular response (MMR) was obtained by 38% and 53% of patients at 1 and 2 years. Twenty patients (19.6%) discontinued treatment with imatinib; six of them did so in the initial 2 years of treatment (4 for resistance and 2 for adverse events). We observed seven deaths (6.86%). Overall survival (OS) at 6 years is 95.1% (95% C.I. 90-100%) and is not different from that of the general population. No patient experienced progression of disease (95% C.I.: 0-3%). Our results suggest that patient management is a crucial point to obtain a successful therapeutic outcome: at 1 year CCyR and MMR rates are similar to the results obtained with second generation TKIs and OS is not different from that of the general population

Published
2014

3. Grandes vitesses, Métropolisation et Organisation des territoires : l'apport de l'intermodalité aéro-ferroviaire à grande vitesse au rayonnement métropolitain

Author

BOZZANI, S

Subjects
TRANSPORT AERIEN, AMENAGEMENT DU TERRITOIRE, INTERMODALITE, DEVELOPPEMENT, ZONE URBAINE, ETUDE D'IMPACT, GEOGRAPHIE, REGION, TRANSPORT FERROVIAIRE, THESE, METROPOLE, GRANDE VITESSE, ACCESSIBILITE, INTERCONNEXION, AEROPORT
Abstract

La mesure de l'apport de l'intermodalité aéro-ferroviaire à grande vitesse au rayonnement métropolitain est au coeur de la problématique sur les relations entre les réseaux et les territoires. Dans le contexte de la construction des espaces de coopérations métropolitaines basées sur des réseaux de villes et une organisation polycentrique, le raisonnement n'est-il pas modifié vers l'inscription de l'espace métropolitain dans sa globalité au coeur d'un système de transport intégré ? L'hypothèse générale s'inscrit dans l'aphorisme suivante les grandes vitesses créent la métropole mais également les espaces métropolitains. La thèse introduit l'idée que pour rendre compte de l'ouverture des espaces métropolitains, un raisonnement multi-échelles et multimodal est nécessaire pour interroger le système de transport intégré des grandes vitesses et insérer une logique intermodale. L'intermodalité aéro-ferroviaire à grande vitesse analysée dans une gamme de configurations à travers la mobilisation d'indicateurs d'accessibilité horaire montre une diffusion des possibilités d'ouverture métropolitaine. Elle propose une nouvelle représentation des liens entre grandes vitesses et territoires remettant en cause les mesures du rayonnement des villes basé sur la possession d'une infrastructure aéroportuaire et le potentiel d'échanges des villes à partir de cette seule infrastructure.

Published
2006

4. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.

Author

Viganò I, Di Giacomo N, Bozzani S, Antolini L, Piazza R, and Gambacorti Passerini C

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Follow-Up Studies, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Male, Middle Aged, Retrospective Studies, Survival Rate, Benzamides administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Piperazines administration & dosage, Protein Kinase Inhibitors administration & dosage, Pyrimidines administration & dosage
Abstract

Imatinib mesylate radically changed the natural history of chronic myeloid leukemia (CML). The recent availability of alternative tyrosine kinase inhibitors (TKIs) renders the clinical management of CML more complex. In this article, we summarize our long-term single institution experience. From 2003 to 2012, 102 patients with newly diagnosed chronic phase CML were referred to our institution and treated with imatinib mesylate as first-line therapy. All patients were followed inside a dedicated CML clinic. At 1 year, 82/95 patients (86.3%) achieved complete cytogenetic response (CCyR) using a treatment performed analysis (TPA); when using an intention to treat analysis, 85/102 patients (83.3%) obtained CCyR. At 3 months, 58 patients (64.4% TPA) obtained a BCR-ABL transcripts level <10%. A major molecular response (MMR) was obtained by 38% and 53% of patients at 1 and 2 years. Twenty patients (19.6%) discontinued treatment with imatinib; six of them did so in the initial 2 years of treatment (4 for resistance and 2 for adverse events). We observed seven deaths (6.86%). Overall survival (OS) at 6 years is 95.1% (95% C.I. 90-100%) and is not different from that of the general population. No patient experienced progression of disease (95% C.I.: 0-3%). Our results suggest that patient management is a crucial point to obtain a successful therapeutic outcome: at 1 year CCyR and MMR rates are similar to the results obtained with second generation TKIs and OS is not different from that of the general population., (© 2014 Wiley Periodicals, Inc.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results